CN115702352A - 因突触功能不全引起的疾病或附带突触功能不全的疾病的判定方法 - Google Patents

因突触功能不全引起的疾病或附带突触功能不全的疾病的判定方法 Download PDF

Info

Publication number
CN115702352A
CN115702352A CN202180043301.0A CN202180043301A CN115702352A CN 115702352 A CN115702352 A CN 115702352A CN 202180043301 A CN202180043301 A CN 202180043301A CN 115702352 A CN115702352 A CN 115702352A
Authority
CN
China
Prior art keywords
synaptic
insufficiency
darps
disease
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043301.0A
Other languages
English (en)
Chinese (zh)
Inventor
白尾智明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almeide Co
Original Assignee
Almeide Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almeide Co filed Critical Almeide Co
Publication of CN115702352A publication Critical patent/CN115702352A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202180043301.0A 2020-06-19 2021-06-18 因突触功能不全引起的疾病或附带突触功能不全的疾病的判定方法 Pending CN115702352A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020106421A JP7244931B2 (ja) 2020-06-19 2020-06-19 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
JP2020-106421 2020-06-19
PCT/JP2021/023135 WO2021256550A1 (ja) 2020-06-19 2021-06-18 シナプス機能不全に起因する疾病、又はシナプス機能不全を付随する疾病の判定方法

Publications (1)

Publication Number Publication Date
CN115702352A true CN115702352A (zh) 2023-02-14

Family

ID=79244367

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043301.0A Pending CN115702352A (zh) 2020-06-19 2021-06-18 因突触功能不全引起的疾病或附带突触功能不全的疾病的判定方法

Country Status (5)

Country Link
US (1) US20230349925A1 (https=)
EP (1) EP4170032A4 (https=)
JP (3) JP7244931B2 (https=)
CN (1) CN115702352A (https=)
WO (1) WO2021256550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4632384A1 (en) * 2022-12-05 2025-10-15 AlzMed, Inc. Method for determining cognitive dysfunction stage
WO2025177848A1 (ja) * 2024-02-22 2025-08-28 アルメッド株式会社 ドレブリン由来のｉＭＡＤＰ、ｉＭＡＤＰを測定する方法及びｉＭＡＤＰの測定用キット

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4568463B2 (ja) * 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP2003180361A (ja) * 2001-12-13 2003-07-02 Japan Science & Technology Corp ｓ−ドレブリンＡ
WO2004007674A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal and retinal gene expression patterns
JP4550530B2 (ja) * 2004-09-03 2010-09-22 独立行政法人科学技術振興機構 シナプス成熟障害モデル動物
JP2016040540A (ja) * 2014-08-13 2016-03-24 国立大学法人群馬大学 ドレブリンａ及びドレブリンｅの特異的定量法
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
JP7111494B2 (ja) 2018-04-05 2022-08-02 グローリー株式会社 光検出センサ、光検出装置、シート類処理装置および光検出方法
JP7324994B2 (ja) * 2018-05-08 2023-08-14 アルメッド株式会社 ドレブリンに特異的に結合するペプチド、及びそのペプチドを用いたドレブリンの検出方法
CN109490527B (zh) * 2018-11-08 2020-01-21 温州医科大学 Dbn1蛋白在制备神经变性疾病诊断药物中的应用
JP7536240B2 (ja) * 2019-03-13 2024-08-20 国立大学法人群馬大学 Ｎｍｄａ受容体阻害活性のハイスループット評価方法
JP7416399B2 (ja) * 2019-10-08 2024-01-17 アルメッド株式会社 アルツハイマー病モデル非ヒト動物及びその製造方法

Also Published As

Publication number Publication date
US20230349925A1 (en) 2023-11-02
EP4170032A4 (en) 2024-12-18
JP2023075214A (ja) 2023-05-30
WO2021256550A1 (ja) 2021-12-23
EP4170032A1 (en) 2023-04-26
JP7244931B2 (ja) 2023-03-23
JP7620340B2 (ja) 2025-01-23
JP2025060925A (ja) 2025-04-10
JP2022001838A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
Majbour et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Shepheard et al. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis
Mollenhauer et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
CA2937169C (en) Biomarker and methods for early diagnosis of alzheimer's disease
Kac et al. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
Gibbons et al. Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
Tanaka et al. ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis
JP2025060925A (ja) シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
KR101883515B1 (ko) 알츠하이머 병의 진단약 및 진단 방법
WO2011005628A1 (en) Detection of neurodegenerative disease
Lennol et al. Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
US20190113528A1 (en) Diagnostic marker for dementia and method for identifying contraction of dementia using said marker
KR20230147081A (ko) 알츠하이머 병의 단계 및 진행에 따른 csf tau 종의검출 방법, 및 이의 용도
KR20190048788A (ko) 타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
US20160018416A1 (en) New dual biomarker of neurodegeneration and of neuroregeneration
JP2025073338A (ja) アルツハイマー病罹患者の認知機能障害の進行リスク又は発症リスクの検査方法、及びアルツハイマー病の検査方法
Guo et al. Autoantibody to the Rab6A/Rab6B in Autoimmune Cerebellar Ataxia Associated with Sjogren’s Syndrome
Daniele et al. α-Synuclein heteromers with ß-amyloid and tau decreased in red blood cells of Alzheimer’s disease and Lewy Body dementia patients.
Arastoo et al. Quantification of plasma tau species containing the proline-rich region as a biomarker in Alzheimer’s disease
Mansour et al. Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression
Taha Biomarkers in CNS-originating Extracellular Vesicles for Parkinson’s disease and Multiple System Atrophy
Goto et al. Plasma acetylated α-synuclein as a novel quantitative biomarker for Parkinson's disease
Qiang et al. CSF 14-3-3ζ is associated with tau pathology and elevated across the Alzheimer’s disease continuum
JP2025181797A (ja) アルツハイマー病の検査方法およびアルツハイマー病の検査キット

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination